Vysis UroVysion™

Detect bladder cancer recurrence

up to 6 months sooner than other diagnostic methods[1]

Earlier detection is the key to increased survival

Vysis UroVysion's™ molecular cytology combines the strength of urine cytology (morphology) with molecular (DNA-based) technology to enhance the detection of the presence of cancer

- Offers greater sensitivity than tests such as cytology or biomarkers, which translates into fewer false negatives
- Earlier detection allows you to treat your patient's cancer more aggressively as needed
- Detects high grade pT1 and pTis tumors that can be overlooked with traditional diagnostic methods and have high progression rates to muscle-invasive cancer
- Provides results you can count on – Vysis UroVysion™ is the first FDA-approved genomic DNA-probe test for identifying early recurrence of bladder cancer
- Not affected by BCG Immunotherapy



With Vysis UroVysion™ you now have a superior option to accurately manage bladder cancer recurrence

Quest Diagnostics®

Quest Diagnostics

Sensitivity

Vysis UroVysion™ is not only more sensitive than urine cytology by stage, but also more sensitive by grade.





Specificity

The specificity of Vysis UroVysion™ is approximately 95% among healthy and non-healthy subjects, which translates to fewer false positives.

Vysis UroVysion™ Images



Normal result observed in an interphase cell obtained from a sample after the Vysis UroVysion™ Bladder Cancer Recurrence Kit hybridization. Each probe signal, CEP 3 (red), CEP 7 (green), CEP 17 (aqua) and LSI p16 (gold) is present in two copies.



Aneusomic interphase cell obtained from a sample showing two copies of chromosome 3 (red), four copies of chromosome 7 (green), five copies of chromosome 17 (aqua) and one copy of p16 gene (gold) after the Vysis UroVysion™ Bladder Cancer Recurrence Kit hybridization.

Accuracy and sensitivity make Vysis UroVysion™ the best method for detecting bladder cancer recurrence

For more information on Vysis UroVysion™ contact your Quest Diagnostics sales representative or visit us at **www.questdiagnostics.com.**

References

1. The source of this claim is the Vysis UroVysion™ Package Insert.
2. Sarosdy, et al. CLINICAL EVALUATION OF A MULTI-TARGET FLOURESCENT IN SITU HYBRIDIZATION ASSAY FOR DETECTION OF BLADDER CANCER. Journal of Urology Nov. 2002.

Quest Diagnostics®